Drawing for AVERTOX

USPTO serial 77737137

AVERTOX

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
LIWINSKI, HELENE AGNES
Law office
TMO LAW OFFICE 100 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with AVERTOX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Chemical additives containing galantamine for use in the manufacture of Tablets, Injections, Aerosols, Gels, Time-Released Products, therapeutic patches, prophylactic patches containing galantamineACTIVE—
005Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals containing galantamine; Drug delivery agents in the form of capsules that provide controlled release of galantamine together with other pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of galantamine together with other pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of galantamine together with other pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of organophosphate toxicity; Inhalers filled with galantamine; Pharmaceutical preparations containing galantamine acting on the central nervous system; Pharmaceutical preparations and substances containing galantamine for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system toxicity related diseases and disorders; Pharmaceutical preparations containing galantamine for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations containing galantamine for the treatment of inflammatory disorders; Pharmaceutical preparations containing galantamine for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention of organophosphate toxicity; Pharmaceutical preparations for the treatment of organophosphate toxicity; Plant extracts containing galantamine for medical, veterinary and pharmaceutical purposes; Syringes sold filled with galantamine; Therapeutic pharmaceutical for the treatment of organophosphate toxicityACTIVE—
016Information leaflets concerning pharmaceuticals containing galantamineACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 18, 2012PC.DPETITION TO DIRECTOR DISMISSED—
Dec 13, 2012MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 13, 2012ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 6, 2012INCEITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST—
Oct 17, 2012APETASSIGNED TO PETITION STAFF—
Aug 20, 2012TPDRTEAS PETITION TO DIRECTOR RECEIVED—
May 31, 2012EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 12, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 11, 2011TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Jul 11, 2011PETGPETITION TO REVIVE-GRANTED—
Jul 11, 2011PROATEAS PETITION TO REVIVE RECEIVED—
Jul 5, 2011MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 5, 2011ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 14, 2011AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 18, 2011TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Jan 18, 2011PETGPETITION TO REVIVE-GRANTED—
Jan 18, 2011PROATEAS PETITION TO REVIVE RECEIVED—
Jan 3, 2011MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 3, 2011ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 1, 2010NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 6, 2010ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Mar 19, 2010CHPBPOST PUBLICATION AMENDMENT - ENTERED—
Mar 16, 2010APETASSIGNED TO PETITION STAFF—
Feb 19, 2010EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Oct 2, 2009ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Sep 22, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 2, 2009NPUBNOTICE OF PUBLICATION—
Aug 19, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 19, 2009ALIEASSIGNED TO LIE—
Aug 13, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 13, 2009XAECEXAMINER'S AMENDMENT ENTERED—
Aug 13, 2009GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 13, 2009GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 13, 2009CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 12, 2009DOCKASSIGNED TO EXAMINER—
May 18, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 18, 2009NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance